Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Vascular events in CML may not be linked to TKI therapy

Vascular events in CML may not be linked to TKI therapy

Coloring can help cancer patients cope with stress

Coloring can help cancer patients cope with stress

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

Scientists find surprising link between iPS cell reprogramming, blood cell formation and cancer

Scientists find surprising link between iPS cell reprogramming, blood cell formation and cancer

STING agonists developed to induce cellular death in B cell malignancies

STING agonists developed to induce cellular death in B cell malignancies

Hematopoietic reprogramming can lead to differentiated blood products for cell-replacement therapy

Hematopoietic reprogramming can lead to differentiated blood products for cell-replacement therapy

ACGT awards new research grants to take researchers to next level in cancer treatment

ACGT awards new research grants to take researchers to next level in cancer treatment

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Leukemia researchers uncover protein that allows blood cancers to develop

Leukemia researchers uncover protein that allows blood cancers to develop

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

Rice university researchers uncover elusive lung cancer cells

Rice university researchers uncover elusive lung cancer cells

Researchers find Achilles' heel of acute lymphoblastic leukemia

Researchers find Achilles' heel of acute lymphoblastic leukemia

Potential link between PLCD and ALL could offer new targets for cancer prevention research

Potential link between PLCD and ALL could offer new targets for cancer prevention research

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Protein p62 acts as molecular brake to keep inflammation in check, avoid collateral damage

Protein p62 acts as molecular brake to keep inflammation in check, avoid collateral damage

IMP's Johannes Zuber receives German Cancer Prize 2016

IMP's Johannes Zuber receives German Cancer Prize 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Ohio State researchers working on new way to treat drug-resistant cancer

Ohio State researchers working on new way to treat drug-resistant cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.